CTSI – PLACE Study:
Have you been diagnosed with Hepatitis C (HCV) and HIV? Interested in cardiovascular health? If yes, come join our
study to help determine if HCV adds to the risk for heart disease in HCV/HIV co-infected patients. Some studies have
shown that people infected with HIV are at a higher risk for developing heart related problems, including heart attacks.
It is unclear if HCV adds to the risk for heart disease, and if treatment for HCV would reduce the risk of heart related
problems. The main purpose of the current study is to try to understand if having HCV makes people with HIV more
likely to have heart disease. The study will also try to see if there are blood tests that can better predict this risk than
the ones already routinely used, and if HCV treatment can help reduce the risk of heart problems. Compensation
To learn more about the study call us at (310) 557-9640.
ACTG 5320 - Viral Hepatitis C Infection Long-Term Cohort Study (V-HICS):
Have you completed Hepatitis C treatment within the past year? If yes, you may be able to join a study where your
experience can help us develop better ways to treat Hepatitis C. This 5-year study is for HIV-positive and HIVnegative
people. It will help us understand how Hepatitis C treatment impacts a person’s health and more about
resistance to the new Hepatitis C medicines and how it may affect future treatments. Study visits are twice a year, plus
a visit before starting any new Hepatitis C treatment. No new medicines are provided by the study. Compensation
To learn more about the study call us at (310) 557-9062.
What is Hepatitis C?
Hepatitis C is a contagious liver disease that results from infection with the Hepatitis C virus (HCV). It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C is usually spread when blood from a person infected with HCV enters the body of someone who is not infected. Today, most people become infected with HCV by sharing needles or other equipment to inject drugs.
Hepatitis C can be either "acute" or "chronic." Acute Hepatitis C virus infection is a short-term illness that occurs within the first 6 months after someone is exposed to HCV. For most people, acute infection leads to chronic infection. Chronic Hepatitis C is a serious disease than can result in long-term health problems, or even death.
There are several strains (types) of hepatitis C found in the United States which are known as genotypes. Different medications have been shown to be effective in decreasing the amount of HCV in the blood, which can help to reduce liver damage from HCV.
What about Hepatitis C and HIV Co-Infection?
About one quarter of HIV-infected persons in the United States are also infected with HCV. HCV is one of the most important causes of chronic liver disease in the United States and HCV infection progresses more rapidly to liver damage in HIV-infected persons. HCV infection may also impact the course and management of HIV infection.
The UCLA CARE Center is conducting research studies for participants either mono-infected only with HCV or co-infected with HCV and HIV. These studies test to see if new drugs are helpful in reducing the amount of HCV in the blood, as well as to see how much medicine is needed to be most effective in reducing HCV.
How can I learn more?
For more information about the UCLA CARE Center and our research on HCV and HIV/HCV, or to find out if you qualify for any of our studies, please contact us:
Phone: (310) 557-9062